Bruker Daltonics, Billerica, Mass, will support the VeriStrat diagnostic test from Biodesix Inc, Boulder, Colo, as well as future diagnostic tests based on matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
VeriStrat is a novel, multivariate serum protein test that helps oncologists personalize therapy for patients with lung cancer.
The new collaboration furthers the companies’ ongoing relationship concerning use of Bruker’s state-of-the-art MALDI-TOF instruments with VeriStrat and other clinical diagnostics in development.
|MALDI-TOF mass spec is a powerful analytical platform that can provide detailed and discriminating information about complex biological samples, but with relatively simple sample prep and high throughput.|
“We have been impressed with Biodesix’ capabilities for development of MALDI-TOF mass spectrometry-based diagnostic assays,” says Gary Kruppa, vice president for business development, Bruker Daltonics. He says the company looks forward to working more closely with Biodesix to support its goals, which could also increase the market for Bruker’s MALDI-TOF mass spectrometers in diagnostics.